tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of John Newman, 124 are a BUY (83.78%), 24 are a HOLD (16.22%).
Analyst John Newman, currently employed at CANACCORD, carries an average stock price target met ratio of 36.65% that have a potential upside of 20.21% achieved within 127 days.
John Newman’s has documented 272 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ATRA, Atara Biotherapeutics at 17-Jan-2025.
Analyst best performing recommendations are on ATRA (ATARA BIOTHERAPEUTICS).
The best stock recommendation documented was for ATRA (ATARA BIOTHERAPEUTICS) at 11/9/2023. The price target of $13 was fulfilled within 11 days with a profit of $7 (116.67%) receiving and performance score of 106.06.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$57
$21.78 (61.84%)
$55
2 months 12 days ago
(10-Dec-2024)
5/6 (83.33%)
$10.98 (23.86%)
84
Buy
$75
$39.78 (112.95%)
$53
2 months 13 days ago
(09-Dec-2024)
6/7 (85.71%)
$26.36 (54.19%)
477
Buy
$51
$15.78 (44.80%)
4 months 12 days ago
(10-Oct-2024)
1/1 (100%)
$9.18 (21.95%)
27
Hold
$56
$20.78 (59.00%)
$61
4 months 26 days ago
(27-Sep-2024)
10/13 (76.92%)
$10.39 (22.78%)
223
Hold
$46
$10.78 (30.61%)
$30
8 months 9 days ago
(13-Jun-2024)
4/4 (100%)
$-0.77 (-1.65%)
169
Which stock is John Newman is most bullish on?
Which stock is John Newman is most reserved on?
What Year was the first public recommendation made by John Newman?
